Two SNP deals for Gemini

Hodgson, John
May 2000
Nature Biotechnology;May2000, Vol. 18 Issue 5, p475
Academic Journal
Reports that at the beginning of April 2000, Great Britain-based Gemini Genomics entered single nucleotide polymorphism-centered collaborations with New Haven, Connecticut-based CuraGen Corp. and San Diego, California and Hamburg, Germany-based Sequenom Inc. Provision of population genetics-based validation for single-base variations in human genes; Reference to 2000 issue for the journal 'Biotechnology,' vol. 18 366.


Related Articles

  • Sequenom steps toward drug development. Dorey, Emma // Nature Biotechnology;Jul2001, Vol. 19 Issue 7, p600 

    Reports on the multi-million dollar merger of San Diego, California-based genetic analysis firm Sequenom Inc. and Cambridge, England-based clinical genomics company Gemini Genomics PLC on May 29, 2001. Unique features of the deal; Advantages of the deal to Sequenom; Expectations of analysts...

  • Differentiation and integration.  // Nature Biotechnology;Jul2001, Vol. 19 Issue 7, p597 

    Editorial. Discusses the merger of biotechnology companies Gemini Genomics PLC and Sequenom Inc. Justification behind the merger of biotechnology companies; Significance of the Gemini and Sequenom merger; Need for integrated collaboration in genomics.

  • breaking news Roundup.  // Chemical Market Reporter;6/4/2001, Vol. 260 Issue 23, p3 

    Presents an update on the chemical industry as of June 4, 2001. Merger of Sequenom Inc. and Gemini Genomics PLC; Move of DuPont Engineering Polymers company to increase the production capacity of Delrin acetal resin at its plant in Dordrecht, Netherlands; Acquisition of the Lumitol acrylic resin...

  • GEMINI DISCOVERS GENE PREDICTOR FOR CONGESTIVE HEART FAILURE.  // Worldwide Biotech;Oct2001, Vol. 13 Issue 10, p5 

    Provides information on the identification of mutations in a gene that may play an important role in the function of human heart muscle, by scientists at Gemini Genomics plc.

  • NEWS BRIEFS.  // MondayMorning;6/7/2010, Vol. 18 Issue 22, p5 

    The article offers news brief related to business. Elizabeth A Dragon, executive of the company Sequenom Inc., pleaded guilty conspiracy to commit securities fraud for lying to investors about the company's prenatal test for Down syndrome. Exelixis Inc., company entered into two financial deals...

  • CuraGen Gets Patents on Interactions Implicated in Cancer.  // Biotech Business;Mar2000, Vol. 13 Issue 3, p2 

    Reports that the United States Patent Office has granted two patents for CuraGen Corporation covering human protein interactions that have been implicated in the division and proliferation of cancer cells.

  • Functional map completed. Dorey, Emma // Nature Biotechnology;Mar2000, Vol. 18 Issue 3, p246 

    Reports on the completion of the first functional genomics map of an entire genome by Connecticut-based Curagen Corp. in collaboration with Stanley Fields at the University of Washington, Seattle, Washington. Analysis of protein interactions in the yeast Saccharomyces cerevisiae; Implications...

  • CuraGen launches subsid. Grisham, Julie // Nature Biotechnology;Jul2000, Vol. 18 Issue 7, p700 

    Report on the launch of corporations to develop technologies for use in drug discovery, preclinical development and pharmacogenetics by New Haven, Connecticut-based CuraGen Corp. Possible development of software for using entire genome knowledge; Details of stakes of CuraGen.

  • CuraGen reports revenue increased 63% last year.  // Biotech Financial Reports;Mar2000, p1 

    Reports on the financial performance posted by New Haven, Connecticut-based biotechnology firm CuraGen Corp. for the fourth quarter and the year ended December 31, 1999. Pharmaceutical companies with which CuraGen established collaborations; Asset impairment charge; Application of genomics to...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics